ALK and lung carcinoma: The discovery of anaplastic lymphoma kinase (ALK)-rearranged lung cancer and the development of the first-line targeted inhibitor alectinib (ALC) have resulted in a markedly higher number of patients achieving more than 2 years of progression-free survival (PFS)3–7.